Changes to the US FDA’s biosimilar application assessment process suggested by a consulting firm and industry seem small, but implementation within the agency could be a challenge.
Adjustments such as providing sponsors advance notice when information requests will be sent were suggested during a meeting to discuss...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?